SMPD1 and neoplasm: Siramesine and several clinically relevant ASM inhibitors were found to trigger cancer-selective lysosomal cell death, displaying great anticancer potential as evident by reducing tumor growth in vivo, and reverting multidrug resistance (Figure 5) (121).